Pacira Pharma (PCRX) Tops Q4 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Pacira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
February 28, 2018 8:00 AM EST-- EXPAREL® net product sales expected to be in the range of $300 to $310 million in 2018 --
-- Conference call today at 8:30 a.m. ET --
PARSIPPANY, N.J., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today reported financial results for the fourth quarter and full year of 2017 and its outlook for 2018.
2017 was a year of solid progress and set the stage for an important year ahead, said Dave Stack, chairman and chief executive officer of Pacira. EXPAREL has now been used in... More
